Higher doses (e.g Wegovy 2.4 mg) may work faster than lower doses
In clinical trials, patients lost an average of 2% of their body weight per month for the first six months, then 1% per month for the next six months, totaling a 16% weight loss by the end of the first year
Oral semaglutide is FDA-approved for people with type 2 diabetes, but it has also shown promise in those with obesity, even without diabetes

Approval (2017) FDA News Release: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (March 08, 2024) Once-Weekly Semaglutide for Weight Management: A Clinical Review - PMC Once-Weekly Semaglutide in Adults With Overweight or Obesity (March 2021) Oral Semaglutide Versus Subcutaneous Liraglutide And Placebo In Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial Efficacy And Safety Of Once-Weekly Semaglutide 20 Mg Versus 10 Mg In Patients With Type 2 Diabetes (Sustain Forte): A Double-Blind, Randomised, Phase 3b Trial (September 2021) Rybelsus Dosing Schedule Ozempic Dosing Schedule Wegovy Dosing Schedule Semaglutide (February 11, 2024) Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes (November 5, 2024) Daily Glucose Profiles After Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus (May 2023)

Most patients taking semaglutide should consume 1.21.6 grams of protein per kilogram of adjusted body weight daily, distributed across 34 meals